TRIQUILAR 28 TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

LEVONORGESTREL; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL; ETHINYL ESTRADIOL; LEVONORGESTREL

Saadav alates:

BAYER INC

ATC kood:

G03AB03

INN (Rahvusvaheline Nimetus):

LEVONORGESTREL AND ESTROGEN

Annus:

125MCG; 30MCG; 40MCG; 50MCG; 30MCG; 75MCG

Ravimvorm:

TABLET

Koostis:

LEVONORGESTREL 125MCG; ETHINYL ESTRADIOL 30MCG; ETHINYL ESTRADIOL 40MCG; LEVONORGESTREL 50MCG; ETHINYL ESTRADIOL 30MCG; LEVONORGESTREL 75MCG

Manustamisviis:

ORAL

Ühikuid pakis:

28

Retsepti tüüp:

Prescription

Terapeutiline ala:

CONTRACEPTIVES

Toote kokkuvõte:

Active ingredient group (AIG) number: 0618648001; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2007-03-08

Toote omadused

_TRIQUILAR Product Monograph _
_Page 1 of 54_
PRODUCT MONOGRAPH
PR
TRIQUILAR
® 21
PR
TRIQUILAR
® 28
0.05 mg levonorgestrel and 0.03 mg ethinyl estradiol tablets
0.075 mg levonorgestrel and 0.04 mg ethinyl estradiol tablets
0.125 mg levonorgestrel and 0.03 mg ethinyl estradiol tablets
USP
Oral Contraceptive
Bayer Inc.
2920 Matheson Boulevard East
Mississauga, Ontario
L4W 5R6
www.bayer.ca
Date of Revision:
May 26, 2017
Submission Control No: 202824
© 2017, Bayer Inc.
® TM see www.bayer.ca/tm-mc
_TRIQUILAR Product Monograph _
_Page 2 of 54_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................13
DRUG INTERACTIONS
..................................................................................................17
DOSAGE AND ADMINISTRATION
..............................................................................23
OVERDOSAGE
................................................................................................................26
ACTION AND CLINICAL PHARMACOLOGY
............................................................27
STORAGE AND STABILITY
..........................................................................................30
SPECIAL HANDLING INSTRUCTIONS
.......................................................................30
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................30
PART II: SCIENTIFIC INFORMATION
.....................................